Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth

• Published in: Molecular cancer therapeutics 2015-04, Vol.14 (4), p.1035-1047
• Main Authors: Gritsina, Galina, Xiao, Fang, O'Brien, Shane W, Gabbasov, Rashid, Maglaty, Marisa A, Xu, Ren-Huan, Thapa, Roshan J, Zhou, Yan, Nicolas, Emmanuelle, Litwin, Samuel, Balachandran, Siddharth, Sigal, Luis J, Huszar, Dennis, Connolly, Denise C
• Format: Article
• Language: English
• Subjects: Analgesics - administration & dosage; Analgesics - pharmacology; Animals; Apoptosis - drug effects; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; Cell Survival - drug effects; Cluster Analysis; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Humans; Integrin alphaVbeta3 - genetics; Integrin alphaVbeta3 - metabolism; Janus Kinases - metabolism; Matrix Metalloproteinases - metabolism; Mice; Mice, Transgenic; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Pyrazoles - administration & dosage; Pyrazoles - pharmacology; Pyrimidines - administration & dosage; Pyrimidines - pharmacology; Signal Transduction - drug effects; STAT3 Transcription Factor - metabolism; Xenograft Model Antitumor Assays
• ISSN: 1535-7163; 1538-8514; 1538-8514
• DOI: 10.1158/1535-7163.mct-14-0800

Ovarian carcinoma is the fifth leading cause of death among women in the United States. Persistent activation of STAT3 is frequently detected in ovarian carcinoma. STAT3 is activated by Janus family kinases (JAK) via cytokine receptors, growth factor receptor, and non-growth factor receptor tyrosine kinases. Activation of STAT3 mediates tumor cell proliferation, survival, motility, invasion, and angiogenesis, and recent work demonstrates that STAT3 activation suppresses antitumor immune responses and supports tumor-promoting inflammation. We hypothesized that therapeutic targeting of the JAK/STAT3 pathway would inhibit tumor growth by direct effects on ovarian carcinoma cells and by inhibition of cells in the tumor microenvironment (TME). To test this, we evaluated the effects of a small-molecule JAK inhibitor, AZD1480, on cell viability, apoptosis, proliferation, migration, and adhesion of ovarian carcinoma cells in vitro. We then evaluated the effects of AZD1480 on in vivo tumor growth and progression, gene expression, tumor-associated matrix metalloproteinase (MMP) activity, and immune cell populations in a transgenic mouse model of ovarian carcinoma. AZD1480 treatment inhibited STAT3 phosphorylation and DNA binding, and migration and adhesion of cultured ovarian carcinoma cells and ovarian tumor growth rate, volume, and ascites production in mice. In addition, drug treatment led to altered gene expression, decreased tumor-associated MMP activity, and fewer suppressor T cells in the peritoneal TME of tumor-bearing mice than control mice. Taken together, our results show pharmacologic inhibition of the JAK2/STAT3 pathway leads to disruption of functions essential for ovarian tumor growth and progression and represents a promising therapeutic strategy.